What question did this study set out to answer?

This review aims to evaluate the clinical efficacy, safety, and optimal use of romiplostim in severe aplastic anemia treatment.

May 11, 2026Annals of HematologyOpen Access

Romiplostim in the management of severe aplastic anemia: a comprehensive clinical review

View Full Paper

Ask AI

Bookmark

Authors

Comprehensive clinical review reveals romiplostim's safety and efficacy in severe aplastic anemia, suggesting it may benefit refractory cases.

This review aims to evaluate the clinical efficacy, safety, and optimal use of romiplostim in severe aplastic anemia treatment.
Conducted a systematic literature search in PubMed, Web of Science, and Scopus.
Included studies: prospective trials, retrospective cohorts, and mechanistic studies reporting on hematologic response.
Reviewed data from 19 studies involving over 390 severe aplastic anemia patients.
Hematologic response rates with romiplostim ranged from 41% to 95%, with up to 55% achieving trilineage recovery.
High-dose regimens (10-20 µg/kg/week) showed superior outcomes, especially in eltrombopag-refractory patients.
Long-term use was well tolerated, with low rates of clonal evolution and serious toxicity.

Saleh et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Comprehensive clinical review reveals romiplostim's safety and efficacy in severe aplastic anemia, suggesting it may benefit refractory cases.